کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10908899 | 1087816 | 2013 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
DLTEMSAAMLDSMCInhibitor of NF-kBMTDMDSNF-kBLSCFACSElectrophoretic mobility shift assay - آزمون تحرک تحرک الکتروفورزIdarubicin - ایداروبیسینBortezomib - بورتِـزومیبMaximum tolerated dose - حداکثر دوز قابل تحملfluorescence-activated cell sorting - دسته بندی سلول های فعال فلورسنسdose-limiting toxicity - دوز محدود کننده سمیتElderly - سالمندیleukemic stem cell - سلول های بنیادی لوسمیmyelodysplastic syndrome - سندرم میلودیسپلاستیکnuclear factor kappa B - فاکتور هسته ای کاپا Bacute myeloid leukemia - لوسمی حاد میلوئیدی یا به اختصار AML
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia](/preview/png/10908899.png)
چکیده انگلیسی
We report the results of a phase I study with four dose levels of bortezomib in combination with idarubicin. Eligible patients were newly diagnosed with acute myeloid leukemia (AML) age â¥60 years, or any adult with relapsed AML. Bortezomib was given twice weekly at 0.8, 1.0, or 1.2 mg/m2 with once weekly idarubicin 10 mg/m2 for four weeks. Twenty patients were treated: 13 newly diagnosed (median age 68, range 61-83) and 7 relapsed (median age 58, range 40-77). Prior myelodysplastic syndrome (MDS) was documented in 10/13 (77%) newly diagnosed and 1/7 (14%) relapsed patients; the three newly diagnosed patients without prior MDS had dyspoietic morphology. Two dose-limiting toxicities occurred at the initial dose level (bortezomib 0.8 mg/m2 and idarubicin 10 mg/m2); idarubicin was reduced to 8 mg/m2 without observing subsequent dose-limiting toxicities. The maximum tolerated dose in this study was bortezomib 1.2 mg/m2 and idarubicin 8 mg/m2. Common adverse events included: neutropenic fever, infections, constitutional symptoms, and gastrointestinal symptoms. No subjects experienced neurotoxicity. Most patients demonstrated hematologic response as evidenced by decreased circulating blasts. Four patients (20%) achieved complete remission. There was one treatment-related death. The combination of bortezomib and idarubicin in this mostly poor-risk, older AML group was well tolerated and did not result in high mortality. This trial was registered at www.clinicaltrials.gov as #NCT00382954.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 37, Issue 11, November 2013, Pages 1502-1508
Journal: Leukemia Research - Volume 37, Issue 11, November 2013, Pages 1502-1508
نویسندگان
Dianna S. Howard, Jane Liesveld, Gordon L. II, John Hayslip, Heidi Weiss, Craig T. Jordan, Monica L. Guzman,